Please provide your email address to receive an email when new articles are posted on . In patients with psoriatic arthritis, secukinumab and adalimumab demonstrated similar results regarding ...

This retrospective study showed that anti–interleukin-17 drug secukinumab yielded favorable results in a small group of patients with severe hidradenitis suppurativa (HS). Researchers of a new study ...

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar. Both secukinumab ...

Among patients with spondyloarthritis (SpA) who initiated or switched to either secukinumab or TNF inhibitors, secukinumab demonstrated greater 4‑year persistence, with fewer discontinuations owing to ...

FUTURE 1 is an ongoing, 2-year, phase 3 study assessing the effect of secukinumab on signs and symptoms, joint structural damage, physical function, and quality of life among patients with psoriatic ...